BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29879883)

  • 1. ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy.
    Marinelli O; Nabissi M; Morelli MB; Torquati L; Amantini C; Santoni G
    Curr Protein Pept Sci; 2018; 19(11):1107-1113. PubMed ID: 29879883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
    Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
    Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
    Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
    Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICOS
    Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
    Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.
    Amatore F; Gorvel L; Olive D
    Expert Opin Ther Targets; 2018 Apr; 22(4):343-351. PubMed ID: 29468927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
    Solinas C; Gu-Trantien C; Willard-Gallo K
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
    Amatore F; Gorvel L; Olive D
    Expert Opin Biol Ther; 2020 Feb; 20(2):141-150. PubMed ID: 31738626
    [No Abstract]   [Full Text] [Related]  

  • 8. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.
    Watanabe M; Hara Y; Tanabe K; Toma H; Abe R
    Int Immunol; 2005 Mar; 17(3):269-78. PubMed ID: 15668466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
    Rujas E; Cui H; Sicard T; Semesi A; Julien JP
    Nat Commun; 2020 Oct; 11(1):5066. PubMed ID: 33033255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming.
    Ogata M; Ito T; Shimamoto K; Nakanishi T; Satsutani N; Miyamoto R; Nomura S
    Int Immunol; 2013 Mar; 25(3):171-82. PubMed ID: 23125331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
    Sainson RCA; Thotakura AK; Kosmac M; Borhis G; Parveen N; Kimber R; Carvalho J; Henderson SJ; Pryke KL; Okell T; O'Leary S; Ball S; Van Krinks C; Gamand L; Taggart E; Pring EJ; Ali H; Craig H; Wong VWY; Liang Q; Rowlands RJ; Lecointre M; Campbell J; Kirby I; Melvin D; Germaschewski V; Oelmann E; Quaratino S; McCourt M
    Cancer Immunol Res; 2020 Dec; 8(12):1568-1582. PubMed ID: 32999002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.
    Le KS; Thibult ML; Just-Landi S; Pastor S; Gondois-Rey F; Granjeaud S; Broussais F; Bouabdallah R; Colisson R; Caux C; Ménétrier-Caux C; Leroux D; Xerri L; Olive D
    Cancer Res; 2016 Aug; 76(16):4648-60. PubMed ID: 27246829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating mast cells stimulate ICOS
    Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
    J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy.
    Zhao X; Wang Y; Jiang X; Mo B; Wang C; Tang M; Rong Y; Zhang G; Hu M; Cai H
    BMC Cancer; 2023 Feb; 23(1):194. PubMed ID: 36855091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells.
    Witsch EJ; Peiser M; Hutloff A; Büchner K; Dorner BG; Jonuleit H; Mages HW; Kroczek RA
    Eur J Immunol; 2002 Sep; 32(9):2680-6. PubMed ID: 12207353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.
    Bellinghausen I; Klostermann B; Böttcher I; Knop J; Saloga J
    Immunology; 2004 May; 112(1):80-6. PubMed ID: 15096187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
    Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
    Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells.
    Zheng Z; Xu PP; Wang L; Zhao HJ; Weng XQ; Zhong HJ; Qu B; Xiong J; Zhao Y; Wang XF; Janin A; Zhao WL
    J Exp Clin Cancer Res; 2017 Jun; 36(1):82. PubMed ID: 28637496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.